Karyopharm Therapeutics (KPTI) reported a Q3 2025 Net Loss of \(33.1M on Total Revenue of \)44.0M (up 14% YoY). However, the nine-month Net Loss widened substantially to \((93.8M)\) compared to \((45.6M)\) in 2024. This widening loss, despite improved operational expense control and lower stock-based compensation (\(10.1M vs \)14.6M), is largely due to a negative swing of approximately \(63M in Other Segment Income/Expenses compared to the prior year. U.S. XPOVIO product revenue remained flat year-to-date (\)82.8M), offset by strong Q3 product revenue growth.
Liquidity and Going Concern: As of Sept
...